MedTrace Logo

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

NCT04895566 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-03-20

No results posted yet for this study

Summary

Phase 0/1 local application of the monoclonal antibody (Mab) sB24M in patients with purulent pyoderma (chronic ulcerative pyoderma) by injection into the affected areas.

Monoclonal antibody (Mab) sB24 negatively regulates immune-inflammatory processes through CD47 / TNF-α Axis promotes epithelialization of damaged tissue.

Conditions

  • Pyoderma
  • Pyoderma Gangrenosum
  • Pyoderma Vegetans
  • Pyoderma Gangrenosum Surrounding Surgical Stoma

Interventions

BIOLOGICAL

Monoclonal antibody (Mab) sB24M

200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.

Sponsors & Collaborators

  • SWISS BIOPHARMA MED GmbH

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2023-03-10
Completion
2023-03-16

Countries

  • Belarus
  • Latvia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04895566 on ClinicalTrials.gov